Sender Co & Partners Inc. lifted its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 315.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,302 shares of the company’s stock after purchasing an additional 80,736 shares during the period. Kenvue accounts for about 2.1% of Sender Co & Partners Inc.’s portfolio, making the stock its 12th largest holding. Sender Co & Partners Inc.’s holdings in Kenvue were worth $2,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also made changes to their positions in the company. Grove Bank & Trust boosted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. boosted its holdings in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Asset Planning Inc acquired a new position in Kenvue in the fourth quarter valued at approximately $42,000. Finally, Clarity Asset Management Inc. acquired a new position in Kenvue in the fourth quarter valued at approximately $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms recently commented on KVUE. Canaccord Genuity Group upped their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. UBS Group upped their price objective on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, May 9th. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective on the stock. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Finally, Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $25.33.
Kenvue Stock Up 1.1%
Shares of NYSE KVUE opened at $24.15 on Friday. The firm has a market cap of $46.34 billion, a price-to-earnings ratio of 45.57, a PEG ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17. The business’s 50 day moving average is $23.16 and its two-hundred day moving average is $22.59.
Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the company earned $0.28 earnings per share. The firm’s quarterly revenue was down 3.9% compared to the same quarter last year. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s payout ratio is currently 149.09%.
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
- Five stocks we like better than Kenvue
- Stock Market Upgrades: What Are They?
- Meta’s 5 Key Pillars for AI Growth—Zuckerberg’s Bold Vision
- Investing In Preferred Stock vs. Common Stock
- Retail Investors Are Betting Big on Rocket Lab—Should You Too?
- 3 Fintech Stocks With Good 2021 Prospects
- GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.